Review: Medical treatment and revascularization may be similar in atherosclerotic renal artery stenosis

Balk, E.; Raman, G.; Chung, M.
May 2007
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p59
Academic Journal
The article presents a study which identifies the effectiveness of management strategies for renal artery stenosis. None of the randomized clinical trials showed a difference between medical treatment and angioplasty without stent placement or surgical revascularization in kidney function or cardiovascular events. The author noted that eligible study designs varied according to interventions and included direct-comparison studies with medical treatment and angioplasty or surgery.


Related Articles

  • Hypertension.  // Current Medical Literature: Cardiology;2007, Vol. 26 Issue 4, p120 

    This article presents citations and editors' notes on several studies on hypertension. They include "Grand Rounds at the British Hypertension Society: Renal Artery Stenosis," by A. J. Brady, I. S. Mackenzie, S. Ritchie et al, "Primary Care Prescribing Patterns in Ireland After the Publication of...

  • Atherosclerotic Renal Artery Stenosis-Diagnosis and Treatment. Lao, David; Parasher, Punit S.; Cho, Kerry C.; Yeghiazarians, Yerem // Mayo Clinic Proceedings;Jul2011, Vol. 86 Issue 7, p649 

    Renal artery stenosis (RAS) is characterized by a heterogeneous group of pathophysiologic entities, of which fibromuscular dysplasla and atherosclerotic RAS (ARAS) are the most common. Whether and which patients should undergo revascularization for ARAS is controversial. The general consensus Is...

  • Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis. Kane, Garvan C.; Xu, Nancy; Mistrik, Erik; Roubicek, Tomas; Stanson, Anthony W.; Garovic, Vesna D. // Nephrology Dialysis Transplantation;Mar2010, Vol. 25 Issue 3, p813 

    Background. Renal artery stenosis (RAS) impacts the pathogenesis and control of heart failure (HF) and may further contribute to increased cardiovascular morbidity and mortality in HF patients. However, the long-term effects of renal artery revascularization on cardiovascular outcomes in HF...

  • Renal artery revascularization: percutaneous stent placement is the standard of practice. White, Christopher J // Vascular Medicine;2002, Vol. 7 Issue 1, p3 

    Editorial. Evaluates issues concerning on the use of revascularization for atherosclerotic aorta-ostial renal artery. Need to acquire endovascular skills in performing revascularization; Risks of renal intervention; Demonstration of randomized trial to determine the safety of the method.

  • Toshiba to start study to validate Time-Slip tech.  // Medical Device Daily;11/30/2010, Vol. 14 Issue 231, p1 

    The article reports on the multi-center trial reported by Toshiba to determine the clinical value of non-contrast Renal magnetic resonance angiography (MRA) using Time-Slip at the 96th Scientific Assembly and Annual Meeting of the Radiology Society of North America. It will involve a prospective...

  • Genetic risk for renal artery stenosis: Association with deletion polymorphism in angiotensin 1-converting enzyme gene. Missouris, Constantinos G.; Barley, Jacqueline; Jeffery, Steve; Carter, Nicholas D.; Singer, Donald R.J.; Macgregor, Graham A. // Kidney International;Feb1996, Vol. 49 Issue 2, p534 

    Atherosclerotic renal artery disease is an important secondary cause of hypertension. Currently, there is great interest in possible genetic determinants of cardiovascular disease: The ACE-D allele has been reported to be associated with increased risk of myocardial infarction as well as...

  • Long-term follow-up after renal artery stenting. Bucek, Robert A.; Puchner, Stefan; Reiter, Markus; Dirisamer, Albert; Minar, Erich; Lammer, Johannes // Wiener Klinische Wochenschrift;2003, Vol. 115 Issue 21/22, p788 

    Background: Renal artery stenosis may cause secondary arterial hypertension and lead to end- stage renal disease. Percutaneous transluminal angioplasty with stent implantation (PTFIAS) allows effective and consistent treatment with a high technical success rate. The present trial focuses on the...

  • 340. Population-based estimate of renovascular disease prevalence among elderly Americans.  // Kidney;May/Jun2003, Vol. 12 Issue 3, p121 

    Objective: To estimate the population-based prevalence of renovascular disease (RVD), defined as ≥60% diameter-reducing renal artery stenosis or occlusion, and define its associations with age, gender, race, and other potential risk factors among participants in the Cardiovascular Health...

  • The effects of Hartcoach, a life style intervention provided by telephone on the reduction of coronary risk factors: a randomised trial. Leemrijse, Chantal J.; van Dijk, Liset; Jørstad, Harald T.; Peters, Ron JG; Veenhof, cindy // BMC Cardiovascular Disorders;2012, Vol. 12 Issue 1, p47 

    Background: Cardiovascular disease (CVD) is the leading cause of death worldwide. Secondary prevention is essential, but participation rates for cardiac rehabilitation are low. Furthermore, current programmes do not accomplish that patients with CVD change their lifestyle in a way that their...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics